| ISSN |
2220-315x (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Systematic Reviews |
| Article Title |
Management of anticoagulation in patients with atrial fibrillation and renal dysfunction: A systematic review
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Anish Kumar, Chander Kumar, Ajay Kumar, Simran Kumari, Aneela, Rahul Rai, Aman Kumar, Kapeel Kumar, Gyaneshwari, Hina Aslam, Inshal Jawed, Farah Alam, Syed Ali Farhan Abbas Rizvi, Muhammad Umair and Agha MW Mirza |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Inshal Jawed, Chief Physician, Senior Researcher, Dow Medical College, Dow University of Health Sciences, Baba-e-urdu Karachi, Karachi 75350, Sindh, Pakistan. inshaljwd@gmail.com |
| Key Words |
Anticoagulation; Atrial fibrillation; Renal dysfunction; Management; Review |
| Core Tip |
Atrial fibrillation (AF) is a common arrhythmia linked to significant morbidity, especially in patients with renal dysfunction. Anticoagulation therapy mitigates thromboembolic risk but poses challenges due to altered drug metabolism and bleeding risks. This systematic review, following PRISMA guidelines, analyzes 16 studies to guide anticoagulant use in this high-risk group. Data extraction covered demographics, renal function, dosing strategies, and outcomes. Quality assessment utilized Cochrane’s Risk of Bias tool and the Newcastle-Ottawa Scale. Evidence favors apixaban for moderate chronic kidney disease and cautious use in end-stage renal disease, stressing individualized treatment. Effective anticoagulation management is crucial for optimizing outcomes in AF patients with renal impairment. |
| Publish Date |
2025-08-12 08:18 |
| Citation |
<p>Kumar A, Kumar C, Kumar A, Kumari S, Aneela, Rai R, Kumar A, Kumar K, Gyaneshwari, Aslam H, Jawed I, Alam F, Rizvi SAFA, Umair M, Mirza AM. Management of anticoagulation in patients with atrial fibrillation and renal dysfunction: A systematic review. <i>World J Exp Med</i> 2025; 15(3): 105485</p> |
| URL |
https://www.wjgnet.com/2220-315X/full/v15/i3/105485.htm |
| DOI |
https://dx.doi.org/10.5493/wjem.v15.i3.105485 |
